$DMTTF News

Last published 3y ago

3y agoCYBN DMTTF TSXV:DMTCybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic TherapeuticsBusiness WireThis news release constitutes a "designated news release" for the purposes of Cybin's prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023. - Combined
3y agoDMTTFSmall Pharma Reports Fiscal Second Quarter 2024 HighlightsGlobeNewswire• Shareholders overwhelmingly vote in favour of Cybin's acquisition of Small Pharma, supporting the combined company's vision to build an international clinical-stage leader in psychedelic-based therapeutics LONDON,
3y agoCYBN DMTTF TSXV:DMTSmall Pharma Obtains Final Order Approving ArrangementBusiness WireSmall Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) ("Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE:CYBN) (NEO:CYBN) ("Cybin"),
3y agoDMTTFSmall Pharma Announces Voting Results from Annual General and Special Meeting of ShareholdersGlobeNewswire• Shareholders overwhelmingly vote in favour of Cybin's acquisition of Small Pharma LONDON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a
3y agoDMTTFSmall Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive DisorderGlobeNewswire• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to
3y agoCYBN DMTTF TSXV:DMTCybin to Acquire Small Pharma Inc.Business Wire- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with
3y agoDMTTFSmall Pharma Reports Fiscal First Quarter 2024 HighlightsGlobeNewswire• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on
3y agoDMTTFSmall Pharma Announces SPL028 R&D Strategy UpdateGlobeNewswire• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company's native DMT program, SPL026,
3y agoDMTTFSmall Pharma Announces Management Team ChangeGlobeNewswireLONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health
3y agoDMTTFSmall Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business HighlightsGlobeNewswire• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a blinded placebo-controlled study • Preliminary findings from SPL028 Phase I clinical trial support target
3y agoDMTTFSmall Pharma Announces Significant Developments In Intellectual Property PortfolioGlobeNewswireLONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health
3y agoDMTTFSmall Pharma to Present at Upcoming CINP World Congress of NeuropsychopharmacologyGlobeNewswireLONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health
3y agoDMTTFSmall Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026GlobeNewswireLONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental
3y agoDMTTFSmall Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in PsychiatryGlobeNewswireLONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental
3y agoDMTTFSmall Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy ResultsGlobeNewswire-Patients' self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers potential in new indications beyond depression LONDON, March
3y agoDMTTFSmall Pharma to Present at Cowen's 43rd Annual Health Care ConferenceGlobeNewswireLONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental
3y agoDMTTFFirst Subject Dosed in Small Pharma's First-in-Human Phase I Clinical Trial with SPL028GlobeNewswireSPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscular LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE)
3y agoDMTTFSmall Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for IssueGlobeNewswireNew United States patents will provide further support for the Company's proprietary position in a key jurisdiction United States grants will bring the Company's total to 16 granted patents and over 90 applications
3y agoDMTTFSmall Pharma Reports Fiscal Third Quarter 2023 HighlightsGlobeNewswirePositive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE
3y agoDMTTFSmall Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive DisorderGlobeNewswireFirst placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant -7.4 point
3y agoDMTTFSmall Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25GlobeNewswireLONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health
3y agoDMTTFFirst Patient Dosed in Small Pharma's Phase I Study Exploring Intramuscular Administration of SPL026GlobeNewswireLONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health
3y agoDMTTFSmall Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual PropertyGlobeNewswireLast patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key pipeline candidates LONDON,
3y agoDMTTFFirst Patient Dosed in Small Pharma's Drug Interaction StudyGlobeNewswireLONDON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health
3y agoDMTTFSmall Pharma To Support University College London Research Project on NeuroplasticityGlobeNewswireLONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health
3y agoDMTTFSmall Pharma to Participate in Upcoming Canaccord Genuity Investor SymposiumGlobeNewswireLONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health
4y agoDMTTFSmall Pharma to Participate in November Investor and Healthcare ConferencesGlobeNewswireLONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health
4y agoDMTTFSmall Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028GlobeNewswireSPL028 is the Company's injectable deuterated DMT candidate with multi-layered IP protection The Phase I study aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration of
4y agoDMTTFSecond United States Patent Granted for Small Pharma's Psychedelics PortfolioGlobeNewswireBrings total to twelve granted patents across the Company's full portfolio LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology
4y agoDMTTFSmall Pharma Reports Fiscal Second Quarter 2023 HighlightsGlobeNewswireLast patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion of 12-week follow up anticipated by year end with data shortly
4y agoDMTTFSmall Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive DisorderGlobeNewswireLONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that i
4y agoDMTTFSmall Pharma Enters Into Automatic Share Purchase PlanGlobeNewswireLONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announced that i
4y agoDMTTFSmall Pharma to Participate in Upcoming September Investor ConferencesGlobeNewswireLONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that George
4y agoDMTTFSmall Pharma Announces TSXV Approval of Normal Course Issuer BidGlobeNewswireLONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that th
4y agoDMTTFSmall Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction StudyGlobeNewswireLONDON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it
4y agoDMTTFCanadian Patent Grant Strengthens Small Pharma's International PositionGlobeNewswireLONDON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as
4y agoDMTTFU.S. Patent Grant to Strengthen Small Pharma's DMT Patent Strategy With Injectable FormulationGlobeNewswireKey U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on
4y agoDMTTFGeorge Tziras to Succeed Peter Rands as Small Pharma Chief Executive OfficerGlobeNewswireBuilding on strong foundations to take Small Pharma through development to commercial success Peter Rands to take on role as Chief Innovation & Intellectual Property Officer LONDON, July 18, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc.
4y agoDMTTFSmall Pharma Reports Fiscal First Quarter 2023 HighlightsGlobeNewswireProgress continues apace with multiple trials expected to enter clinic later this year First US patent granted LONDON, July 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology
4y agoDMTTFSmall Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022GlobeNewswireLONDON, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announc
4y agoDMTTFSmall Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022GlobeNewswireReporting its financial results and continued progress across short-acting psychedelics portfolio Executive team and IP position strengthened LONDON, June 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "
4y agoDMTTFSmall Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022GlobeNewswireLONDON, May 30, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that Peter Ra
4y agoDMTTFSmall Pharma Shares Business Update Ahead of Annual Financial ResultsGlobeNewswire- Appointment of Alastair Riddell as COO- Two new Composition of Matter patents granted for pipeline projects- Progress continues across short-acting psychedelics portfolio LONDON, May 25, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB
4y agoDMTTFSmall Pharma to Participate in the PSYCH Symposium: London 2022GlobeNewswireLONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, will participate in the
4y agoDMTTFSmall Pharma To Present At The KCSA Psychedelics Virtual Investor Conference On April 28, 2022GlobeNewswireLONDON, April 27, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that Peter
4y agoDMTTFSmall Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic AssetsGlobeNewswireLead DMT-assisted therapy candidate SPL026's clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of Matter patent protection in the UK, moves towards P
4y agoDMTTFSmall Pharma to Participate in the 34th Annual Roth ConferenceGlobeNewswireLONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuroscience company focused on psychedelic-assisted therapies for mental health conditions, announces its participation in the 3
4y agoDMTTFWorld's First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase IGlobeNewswireIn the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects on the intensity and quality of the psychedelic experience
4y agoDMTTFSmall Pharma Reports Fiscal Third Quarter 2021 HighlightsGlobeNewswireLONDON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine ("DMT") therapies, has today published its thir
4y agoDMTTFSmall Pharma to Attend Upcoming Healthcare Conferences in January 2022GlobeNewswireLONDON, United Kingdom, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at th